Rita Spilka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8698338/publications.pdf

Version: 2024-02-01

10	288	1478280	1372474
papers	citations	h-index	g-index
10	10	10	528
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Eukaryotic translation initiation factors in cancer development and progression. Cancer Letters, 2013, 340, 9-21.	3.2	130
2	elF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cellular Oncology (Dordrecht), 2014, 37, 253-267.	2.1	48
3	Organotypic three-dimensional cancer cell cultures mirror drug responses (i>in vivo (/i>: lessons learned from the inhibition of EGFR signaling. Oncotarget, 2017, 8, 107423-107440.	0.8	36
4	ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers, 2017, 9, 33.	1.7	25
5	Overexpression of elF3a in Squamous Cell Carcinoma of the Oral Cavity and Its Putative Relation to Chemotherapy Response. Journal of Oncology, 2012, 2012, 1-9.	0.6	23
6	Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines. International Journal of Molecular Sciences, 2020, 21, 4595.	1.8	9
7	The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker Research, 2016, 4, 8.	2.8	6
8	Expression profile of translation initiation factor elF2B5 in diffuse large B-cell lymphoma and its correlation to clinical outcome. Blood Cancer Journal, 2018, 8, 79.	2.8	4
9	Current Coverage of the mTOR Pathway by Next-Generation Sequencing Oncology Panels. International Journal of Molecular Sciences, 2019, 20, 690.	1.8	4
10	The Relevance of Gender in Tumor-Influencing Epigenetic Traits. Epigenomes, 2019, 3, 6.	0.8	3